Laura Holman to Endometrial Neoplasms
                            
                            
                                This is a "connection" page, showing publications Laura Holman has written about Endometrial Neoplasms.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            0.897
         
        
        
     
 
    
        
        - 
            Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial. J Clin Oncol. 2024 Jul 10; 42(20):2425-2435.
            
            
                Score: 0.193
             
- 
            A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. Gynecol Oncol. 2022 07; 166(1):44-49.
            
            
                Score: 0.168
             
- 
            A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study. Gynecol Oncol. 2022 03; 164(3):481-491.
            
            
                Score: 0.165
             
- 
            A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response. Clin Cancer Res. 2021 05 15; 27(10):2734-2741.
            
            
                Score: 0.156
             
- 
            Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy. Gynecol Oncol. 2019 09; 154(3):461-466.
            
            
                Score: 0.138
             
- 
            Update on sentinel lymph node evaluation in gynecologic malignancies. Curr Opin Obstet Gynecol. 2011 Feb; 23(1):8-12.
            
            
                Score: 0.077